Is Medline Inc. (MDLN) A Good Stock To Buy Now?

Is MDLN a bully banal to buy? We came crossed a bullish thesis connected Medline Inc. connected The Pursuit of Compounding’s Substack. In this article, we volition summarize the bulls’ thesis connected MDLN. Medline Inc.'s stock was trading astatine $41.36 arsenic of March 27th. MDLN’s trailing and guardant P/E were 29.91 and 29.24 respectively according to Yahoo Finance.

Medline Industries (MDLN) represents a high-quality, vertically integrated healthcare supplier with a unsocial concern profile, though near-term dynamics are analyzable by backstage equity overhang and structural intricacies. Unlike pure-play distributors specified arsenic McKesson, Cardinal Health, or Cencora, Medline combines manufacturing and logistics, producing astir 190,000 of the 335,000 products it sells and operating 69 planetary distribution centers with implicit 2,000 trucks.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

This standard enables next-day transportation to 95% of the U.S., portion Prime Vendor agreements fastener successful multi-year contracts with a 98% retention rate, driving some gross maturation and high-margin profitability. The proprietary “Medline Brand” conception accounts for implicit 80% of Adjusted EBITDA, offering superior margins and recurring currency flows.

The company’s 2025 IPO raised $7 billion, chiefly to trim indebtedness from the $34 cardinal LBO, lowering involvement disbursal by an estimated $300 cardinal annually and improving escaped currency flow, which reached $1.4 cardinal successful 2024. However, Medline’s analyzable Up-C structure, continued backstage equity ownership of astir 69% of units, and a Tax Receivable Agreement make important near-term risk. As PE sponsors exit, the imaginable surge successful tradable shares could unit the stock, creating a notable overhang.

Operationally, Medline’s operation of manufacturing scale, proprietary products, and resilient logistics positions it for semipermanent compounding, and its beardown currency procreation offers flexibility for M&A oregon shareholder returns. Nevertheless, until the backstage equity overhang and structural uncertainties are resolved, nationalist investors look meaningful near-term downside risk. Consequently, portion the concern itself is exceptionally beardown and strategically defensible, MDLN’s existent equity valuation warrants caution, making it charismatic accidental for agelong word investors.

Previously, we covered a bullish thesis on Medtronic plc (MDT) by Investing Intel successful May 2025, highlighting beardown FY2025 results and the planned spin-off of its diabetes concern to unlock value. MDT’s banal terms has appreciated by approximately 8.01% since our coverage. The Pursuit of Compounding shares a akin presumption but emphasizes Medline Inc.’s (MDLN) vertically integrated operations, high-margin products, and near-term backstage equity overhang.